APPA
Knee Osteoarthritis (with moderate to severe pain and nociplastic pain features)
Phase 2bActive
Key Facts
Indication
Knee Osteoarthritis (with moderate to severe pain and nociplastic pain features)
Phase
Phase 2b
Status
Active
Company
About AKL Therapeutics
AKL Therapeutics is a clinical-stage biotech advancing APPA, an oral senotherapeutic combination drug for osteoarthritis and other age-related diseases. The company has generated positive Phase 2b dose-ranging data showing a pharmacokinetic/pharmacodynamic correlation between higher drug exposure and improved pain reduction. With a patented liquid capsule formulation in development to enhance bioavailability, AKL is planning a PK bridging study followed by a confirmatory Phase 2b/3 trial, positioning itself in a market with few oral, chronic-use OA drug competitors.
View full company profile